GlassScriptPhysician profile
Daniel John Dilworth
NPI 1336219484
$2,700.75
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $292 · 2020: $193 · 2021: $584 · 2022: $1,251 · 2023: $194 · 2024: $187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $381.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $381.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gynesonics, INC. | $604.07 | 2022 | |
| Abbvie INC. | $438.26 | 2019-2022 | |
| Channel Medsystems, INC. | $299.55 | 2022-2024 | |
| Therapeuticsmd, INC. | $185.77 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $185.35 | 2023-2024 | Myfembree |
| Agile Therapeutics, INC. | $140.83 | 2021-2022 | |
| Minerva Surgical, INC | $138.04 | 2021-2022 | |
| Hologic Sales and Service, LLC | $114.44 | 2019-2023 | Acessa Provu System |
| Avion Pharmaceuticals | $102.59 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $51.56 | 2019-2024 | Gardasil, Gardasil 9 |
| Organon LLC | $48.88 | 2021-2022 | |
| Mylan Pharmaceuticals INC. | $46.51 | 2021 | |
| Exeltis, USA INC. | $40.78 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $40.50 | 2020-2021 | |
| Astellas Pharma US INC | $32.29 | 2023-2024 | Veozah |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $31.83 | 2019 | |
| Evofem Biosciences, INC. | $30.35 | 2020-2021 | |
| Scynexis, INC. | $26.05 | 2022 | |
| Dysis Medical, INC. | $24.58 | 2021 | |
| Daiichi Sankyo INC. | $24.29 | 2021 | |
| Mayne Pharma Commercial LLC | $21.92 | 2021-2023 | |
| Coopersurgical, INC. | $19.16 | 2021 | |
| Roche Diagnostics Corporation | $16.36 | 2019 | |
| Pfizer INC. | $14.96 | 2022 | |
| Amag Pharmaceuticals, INC. | $10.98 | 2019 | |
| Meditrina | $10.85 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Dilworth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.